Skip to content

Clinical study on the treatment of neuromyelitis optica spectrum disorders with plasma exchange combined with inebilizumab

Clinical study on the treatment of neuromyelitis optica spectrum disorders with plasma exchange combined with inebilizumab

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500103931
Enrollment
Unknown
Registered
2025-06-09
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NMOSD

Interventions

Plasma exchange+inebilizumab treatment group:None
Plasma exchange+Mycophenolate mofetil group:None

Sponsors

Punan hospital in Pudong new district, Shanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the 2015 international consensus diagnostic criteria for neuromyelitis optica spectrum disease (NMOSD) and are positive for AQP4 antibody; 2. Age greater than or equal to 18 years old; 3. The condition of NMOSD is in the acute stage, that is, there are new neurological deficit symptoms within 30 days before screening, or the original symptoms are aggravated, and the symptoms last for at least 24 hours, and there is no accompanying fever; 4. Agree to use effective contraception for the duration of the study; 5. Voluntarily sign the informed consent form.

Exclusion criteria

Exclusion criteria: 1. Patients with active hepatitis B virus infection, that is, patients with active hepatitis B who are hepatitis B surface antigen (HBsAg) positive and hepatitis B virus antibody positive; 2. Patients with active or untreated latent tuberculosis; 3. Those who may be allergic to inezolizumab as judged by the investigator; 4. Pregnant women, lactating women and patients with birth plans in the past 52 weeks; 5. Patients who, in the opinion of the investigator, are not suitable to participate in the trial.

Design outcomes

Primary

MeasureTime frame
Changes in peripheral plasma cells/B cells;

Secondary

MeasureTime frame
Time of first recurrence after treatment;Number of relapses;Changes in Expanded Disability Status Scale (EDSS) score from baseline (at weeks 28 and 52).;Changes in Hauser Ambulation Index from baseline (at weeks 28 and 52);Changes in OSIS (Optic Spinal Inflammatory Lesion Score) for neuromyelitis optica-type injury from baseline (at weeks 28 and 52);Changes in the number of new T2 lesions on magnetic resonance imaging (MRI) from baseline (at week 52);

Countries

China

Contacts

Public ContactYangtai Guan

Punan Branch of Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine(Punan hospital in Pudong new district, Shanghai)

yangtaiguan@sina.com+86 133 8627 1865

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026